IntelligentMDx said this week that it has entered into a multi-year development and licensing agreement with Qiagen to design, develop, and manufacture several undisclosed assays for use on Qiagen's QiaSymphony RGQ automated molecular testing platform.

For IMDx, the agreement is an "important step" toward fulfilling its goal of becoming a "universal provider of gold-standard molecular diagnostic kits" for use on multiple instrument platforms, Alice Jacobs-Nesselrodt, chairman and CEO of the firm, told PCR Insider this week.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.